경구용 GLP-1 체중 감량제 시장 보고서(2026년)

Oral glucagon-like peptide (GLP)-1 weight loss drugs are orally delivered medications designed to imitate or enhance the activity of the GLP-1 hormone, helping to regulate appetite, delay gastric emptying, and improve blood glucose control, thereby promoting weight reduction. These medications are mainly prescribed for obesity and type 2 diabetes management and provide a non-injectable option compared with traditional GLP-1 treatments.

The primary drug types of oral glucagon-like peptide-1 (GLP-1) weight loss drugs include orforglipron, oral semaglutide, and next-generation oral GLP-1 agents. Orforglipron refers to an oral small-molecule GLP-1 receptor agonist designed to support weight reduction and metabolic control without requiring injectable administration. These drugs are used across patient populations including non-diabetic patients, diabetic patients, adult populations, adolescent populations, and elderly populations and are indicated for obesity management, overweight with comorbidities, type 2 diabetes with obesity, cardiovascular risk reduction, and weight maintenance. They are distributed through retail pharmacy, direct-to-consumer, and hospital pharmacy channels and are utilized by end users including hospitals, obesity clinics, homecare or self-administered users, and specialty metabolic centers.

Tariffs are influencing the oral glucagon-like peptide-1 (GLP-1) weight loss drugs market by increasing costs of imported active pharmaceutical ingredients, advanced formulation technologies, and specialized manufacturing equipment required for oral peptide and small molecule production. This is slowing commercialization efforts and development timelines, particularly in import dependent regions such as Asia-Pacific and parts of Europe. Pharmaceutical companies are also experiencing pricing pressure, which is influencing affordability and reimbursement conditions in obesity and type 2 diabetes treatment segments. Hardware intensive and formulation driven drug categories are the most affected due to complex global sourcing structures. However, tariffs are simultaneously encouraging regional manufacturing expansion, supplier base diversification, and increased investment in localized pharmaceutical production ecosystems.

The oral glucagon-like peptide (GLP)-1 weight loss drug market size has grown exponentially in recent years. It will grow from $18.27 billion in 2025 to $24.76 billion in 2026 at a compound annual growth rate (CAGR) of 35.6%. The growth in the historic period can be attributed to increasing prevalence of obesity and type 2 diabetes, poor patient adherence to injectable therapies, expanding clinical validation of GLP-1 receptor benefits, rising healthcare awareness regarding metabolic disorders, growth in oral drug formulation research.

The oral glucagon-like peptide (GLP)-1 weight loss drug market size is expected to see exponential growth in the next few years. It will grow to $84.18 billion in 2030 at a compound annual growth rate (CAGR) of 35.8%. The growth in the forecast period can be attributed to rising demand for non-invasive weight management solutions, expansion of next-generation oral peptide alternatives, increasing adoption of personalized obesity treatment approaches, improving reimbursement coverage for metabolic therapeutics, and continuous pipeline advancements in small molecule GLP-1 therapies. Major trends in the forecast period include innovation in oral GLP-1 small molecules for weight management, expansion of non-injectable obesity treatment adoption, increasing demand for once-daily metabolic regulation therapies, growing focus on long-term appetite control medications, and a shifting preference toward combination therapies in obesity and type 2 diabetes management.

The rising prevalence of obesity is expected to drive the growth of the oral glucagon-like peptide (GLP)-1 weight loss drug market going forward. Obesity refers to a medical condition characterized by excessive accumulation of body fat that may negatively impact health and increase the risk of diseases such as diabetes, heart disease, and hypertension. The increasing prevalence of obesity is primarily driven by unhealthy dietary habits, including excessive consumption of high-calorie, processed, and sugary foods combined with low levels of physical activity. Oral glucagon-like peptide (GLP)-1 weight loss drugs help manage obesity by regulating appetite, reducing calorie intake, and improving metabolic control, thereby supporting effective and sustained weight reduction. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, from 2023 to 2024, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity, up from 64.0% in 2022 to 2023. Therefore, the increasing prevalence of obesity is driving the growth of the oral glucagon-like peptide (GLP)-1 weight loss drug market.

Leading companies operating in the oral glucagon-like peptide (GLP)-1 weight loss drug market are focusing on the development of non-peptide small molecule solutions, including flexible-dosing oral formulations, to improve patient adherence, broaden accessibility beyond injectable therapies, and achieve enhanced weight loss outcomes. Flexible-dosing oral formulations refer to medications designed to be taken conveniently at varying times or under different conditions without strict requirements related to meals, fluid intake, or precise scheduling. For example, in April 2026, Eli Lilly and Company, a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Foundayo (orforglipron), its once-daily oral GLP-1 receptor agonist, the only non-peptide tablet approved for adults with obesity or overweight conditions accompanied by weight-related comorbidities. Designed to support long-term weight management in conjunction with diet and exercise, the therapy demonstrated an average weight reduction of 27 pounds (12.4%) at the highest dose in the Phase 3 ATTAIN-1 trial compared with 2.2 pounds in the placebo group, along with reductions in cardiovascular risk indicators such as waist circumference and triglycerides.

In November 2025, Pfizer Inc., a US-based pharmaceutical company, acquired Metsera for USD 10 billion. Through this acquisition, Pfizer seeks to reinforce its presence in the fast-expanding obesity and cardiometabolic therapeutics market by broadening its pipeline with next-generation oral and injectable GLP-1 and amylin-based treatment candidates. Metsera Inc. is a US-based biotechnology company focused on developing an oral GLP-1 receptor agonist (RA) for weight management.

Major companies operating in the oral glucagon-like peptide (GLP)-1 weight loss drug market are Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca PLC, Innovent Biologics Inc., Hansoh Pharmaceutical Group, Hanmi Pharmaceutical Co Ltd., Amgen, Jiangsu Hengrui Pharmaceuticals Co Ltd., Viking Therapeutics Inc., Structure Therapeutics Inc., Biomea Fusion Inc., Oramed Pharmaceuticals Inc., Sciwind Biosciences Co. Ltd., Septerna Inc., D And D Pharmatech Inc., Kailera Therapeutics Inc., Eccogene Inc.

North America was the dominant region in the oral glp-1 weight loss drug market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in oral glucagon-like peptide (GLP)-1 weight loss drug report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral glucagon-like peptide (GLP)-1 weight loss drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral glucagon-like peptide (GLP)-1 weight loss drug market consists of sales of oral glucagon-like peptide-1 receptor agonist medications, anti-obesity prescription drugs, and oral metabolic disorder treatment products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The oral glucagon-like peptide (GLP)-1 weight loss drug market research report is one of a series of new reports from The Business Research Company that provides oral glucagon-like peptide (GLP)-1 weight loss drug market statistics, including oral glucagon-like peptide (GLP)-1 weight loss drug industry global market size, regional shares, competitors with a oral glucagon-like peptide (GLP)-1 weight loss drug market share, detailed oral glucagon-like peptide (GLP)-1 weight loss drug market segments, market trends and opportunities, and any further data you may need to thrive in the oral glucagon-like peptide (GLP)-1 weight loss drug industry. This oral glucagon-like peptide (GLP)-1 weight loss drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oral glucagon-like peptide (glp)-1 weight loss drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral glucagon-like peptide (glp)-1 weight loss drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oral glucagon-like peptide (glp)-1 weight loss drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Orforglipron; Oral Semaglutide; Next Generation Oral Glucagon Like Peptide One
• 2) By Patient Type: Non Diabetic Patients; Diabetic Patients; Adult Population; Adolescent Population; Elderly Population
• 3) By Indication: Obesity Management; Overweight With Comorbidities; Type Two Diabetes With Obesity; Cardiovascular Risk Reduction; Weight Maintenance
• 4) By Distribution Channel: Retail Pharmacy; Direct To Consumer; Hospital Pharmacy
• 5) By End User: Hospitals; Obesity Clinics; Homecare Or Self Administered Users; Specialty Metabolic Centers
• Subsegments:
• 1) By Orforglipron: Once Daily Oral Formulations; Small Molecule Glucagon Like Peptide One Therapies; Obesity Management Therapies; Type Two Diabetes Management Therapies; Combination Metabolic Therapies
• 2) By Oral Semaglutide: Tablet Based Peptide Therapies; Once Daily Oral Therapies; Weight Management Therapies; Cardiometabolic Risk Reduction Therapies; Long Term Chronic Weight Control Therapies
• 3) By Next Generation Oral Glucagon Like Peptide One Therapies: Dual Agonist Oral Therapies; Triple Agonist Oral Therapies; Non Peptide Oral Therapies; Extended Release Oral Therapies; Precision Metabolic Therapies
• Companies Mentioned: Novo Nordisk A/S; Eli Lilly and Company; AstraZeneca PLC; Innovent Biologics Inc.; Hansoh Pharmaceutical Group; Hanmi Pharmaceutical Co Ltd.; Amgen; Jiangsu Hengrui Pharmaceuticals Co Ltd.; Viking Therapeutics Inc.; Structure Therapeutics Inc.; Biomea Fusion Inc.; Oramed Pharmaceuticals Inc.; Sciwind Biosciences Co. Ltd.; Septerna Inc.; D And D Pharmatech Inc.; Kailera Therapeutics Inc.; Eccogene Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet Of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Oral GLP 1 Small Molecule Innovation For Weight Management
  • 4.2.2 Expansion Of Non Injectable Obesity Treatment Adoption
  • 4.2.3 Increasing Demand For Once Daily Metabolic Control Therapies
  • 4.2.4 Rising Focus On Long Term Appetite Regulation Drugs
  • 4.2.5 Growing Shift Toward Combination Therapy In Obesity And Type 2 Diabetes Management

5. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Obesity Clinics
• 5.3 Homecare Or Self Administered Users
• 5.4 Specialty Metabolic Centers
• 5.5 Other End Users

6. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Segmentation

• 9.1. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Orforglipron, Oral Semaglutide, Next Generation Oral Glucagon Like Peptide One
• 9.2. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Patient Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Non Diabetic Patients, Diabetic Patients, Adult Population, Adolescent Population, Elderly Population
• 9.3. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Obesity Management, Overweight With Comorbidities, Type Two Diabetes With Obesity, Cardiovascular Risk Reduction, Weight Maintenance
• 9.4. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Retail Pharmacy, Direct To Consumer, Hospital Pharmacy
• 9.5. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Obesity Clinics, Homecare Or Self Administered Users, Specialty Metabolic Centers
• 9.6. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Sub-Segmentation Of Orforglipron, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Once Daily Oral Formulations, Small Molecule Glucagon Like Peptide One Therapies, Obesity Management Therapies, Type Two Diabetes Management Therapies, Combination Metabolic Therapies
• 9.7. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Sub-Segmentation Of Oral Semaglutide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tablet Based Peptide Therapies, Once Daily Oral Therapies, Weight Management Therapies, Cardiometabolic Risk Reduction Therapies, Long Term Chronic Weight Control Therapies
• 9.8. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Sub-Segmentation Of Next Generation Oral Glucagon Like Peptide One Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Dual Agonist Oral Therapies, Triple Agonist Oral Therapies, Non Peptide Oral Therapies, Extended Release Oral Therapies, Precision Metabolic Therapies

10. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Regional And Country Analysis

• 10.1. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 11.1. Asia-Pacific Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 12.1. China Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 13.1. India Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 14.1. Japan Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 15.1. Australia Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 16.1. Indonesia Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 17.1. South Korea Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 18.1. Taiwan Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 19.1. South East Asia Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 20.1. Western Europe Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 21.1. UK Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 22.1. Germany Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 23.1. France Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 24.1. Italy Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 25.1. Spain Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 26.1. Eastern Europe Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 27.1. Russia Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 28.1. North America Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 29.1. USA Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 30.1. Canada Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 31.1. South America Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 32.1. Brazil Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 33.1. Middle East Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

• 34.1. Africa Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market, Segmentation By Drug Type, Segmentation By Patient Type, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Regulatory and Investment Landscape

36. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Competitive Landscape And Company Profiles

• 36.1. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Company Profiles
  • 36.3.1. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Innovent Biologics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Hansoh Pharmaceutical Group Overview, Products and Services, Strategy and Financial Analysis

37. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Other Major And Innovative Companies

• Hanmi Pharmaceutical Co Ltd., Amgen, Jiangsu Hengrui Pharmaceuticals Co Ltd., Viking Therapeutics Inc., Structure Therapeutics Inc., Biomea Fusion Inc., Oramed Pharmaceuticals Inc., Sciwind Biosciences Co. Ltd., Septerna Inc., D And D Pharmatech Inc., Kailera Therapeutics Inc., Eccogene Inc.

38. Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

41. Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market High Potential Countries, Segments and Strategies

• 41.1 Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer